Know Cancer

or
forgot password

A Randomized, Open-label Phase 2 Study of EC145 Single-agent and the Combination of EC145 Plus Docetaxel Versus Docetaxel Alone in Participants With Folate-receptor Positive [FR(++)] Second Line NSCLC


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Non Small Cell Lung Cancer

Thank you

Trial Information

A Randomized, Open-label Phase 2 Study of EC145 Single-agent and the Combination of EC145 Plus Docetaxel Versus Docetaxel Alone in Participants With Folate-receptor Positive [FR(++)] Second Line NSCLC


In a phase 2 study of single-agent EC145 in heavily pretreated non-small cell lung cancer
(NSCLC) patients (median of 3 prior chemotherapy regimens), the subgroup with all target
lesions expressing the folate receptor [FR(++)] had a promising prolonged progression free
survival of 7.1 months and overall survival of 10.9 months. Furthermore, in-vitro and
in-vivo studies in KB models showed good synergism between EC145 and docetaxel.

This study will clinically assess for the first time the combination of EC145+docetaxel (Arm
B) in participants with NSCLC (Stage IIIB or IV). This is an international, multicenter,
centrally randomized, open-label, phase 2 study comparing single-agent EC145,
EC145+docetaxel combination therapy, and single-agent docetaxel in participants with NSCLC
who have failed one prior chemotherapy and who have all target lesions expressing the folate
receptor [FR(++)]. Eligible participants will be randomized in a 1:1:1 ratio into either Arm
A (single-agent EC145), Arm B (EC145+docetaxel combination therapy), or Arm C (single-agent
docetaxel) and will receive treatment until either disease progression or intolerable
toxicity.

This study is intended to investigate if there is a sufficiently strong efficacy signal in
order to proceed with phase 3 testing with either EC145 single-agent and/or the combination
of EC145+docetaxel against the standard-of-care docetaxel in second-line NSCLC.

This study will clinically assess for the first time the combination of EC145+docetaxel (Arm
B) in participants with NSCLC (Stage IIIB or IV). Therefore, an interim safety analysis will
be done by the DSMB after 5 participants in Arm B have completed 1 cycle of therapy, and the
second analysis after 15 participants in Arm B have completed 1 cycle of therapy.

If the majority of the enrolled participants (more than 70%) require a dose reduction of one
level (to 60 mg/m2), the dose will be reduced for the remainder of the study. If the
majority of the participants (more than 70%) require 2 dose reductions (to 40 mg/m2), the
sponsor will consider discontinuing the combination arm.


Inclusion Criteria:



1. Ability to sign an approved informed consent form (ICF).

2. Must be ≥ 18 years of age.

3. Histology confirmed diagnosis of non-small cell lung cancer (adenocarcinoma,
squamous, adenosquamous, or adenocarcinoma with other NSCLC variants of the lung)
(Stage IIIB or IV).

4. All (RECIST v1.1-defined) target lesions positive for the folate receptor [FR(++)] by
SPECT scan.

5. Only one prior systemic therapy for advanced disease (e.g.,a platinum doublet or a
maintenance regimen that includes a platinum doublet; in addition, the participant
may have received an epidermal growth factor receptor [EGFR] inhibitor).

6. Radiological evaluation conducted no more than 28 days prior to beginning study
therapy. If history of CNS metastasis baseline radiological imaging must include
brain MRI or CT.

7. Radiologic evidence of disease progression following the most recent prior treatment.

8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

9. Must have recovered (to baseline/stabilization) from prior
cytotoxic-therapy-associated acute toxicities.

10. Prior radiation therapy is allowed if the following criteria is met:

- Radiation to < 25% of the bone marrow; whole pelvis radiation is excluded.

- Prior radiotherapy must be completed at least 2 weeks before randomization.

- Must have recovered from the acute toxic effects of the treatment before
randomized.

- Prior thoracic radiation must be completed 30 days before study enrollment.

- Irradiated pulmonary lesions cannot be used as target or non-target lesions (and
must be excluded) unless there is previous documented progression of these
lesions.

- Palliative extrathoracic radiotherapy can continue, but these lesions must be
excluded as target and non-target lesions.

11. Adequate organ function:

- Bone marrow reserve: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. Platelets ≥
100 x 109/L. Hemoglobin ≥ 9 g/dL.

- Hepatic: Total bilirubin ≤ 1.5 x the upper limit of normal (ULN). Alanine
aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl
transferase (GGT), and lactate dehydrogenase (LDH) and alkaline phosphatase ≤
2.5 x ULN.

- Renal: Serum creatinine ≤ 1.5 x ULN, or for participants with serum creatinine >
1.5 ULN, creatinine clearance ≥ 50 mL/min/1.73 m2 (50mL/min/1.73m2 is equivalent
to 0.83 mL/s/m2).

12. Participants of childbearing potential:

- Women who are capable of becoming pregnant must have a negative serum pregnancy
test within 1 week prior to exposure to EC20 and within 1 week prior to exposure
to treatment with EC145 and/or docetaxel.

- Women who are capable of becoming pregnant and male participants who are
sexually active must practice an effective method of birth control for the
duration of their participation in the trial through 3 months following the last
dose of EC145 and through 6 months following the last dose of docetaxel.

Exclusion Criteria:

1. Prior therapy with docetaxel, vinorelbine, or vinca-containing compounds.

2. Known hypersensitivity to docetaxel or polysorbate 80.

3. Symptomatic central nervous system (CNS) metastases or metastases that result in
midline shift, significant edema.

4. Malignancies other than NSCLC that are expected to alter life expectancy or may
interfere with disease assessment. Patients with adequately treated non-melanoma skin
cancer, carcinoma in situ of the cervix, or low-grade (Gleason score ≤ 6) localized
prostate cancer and patients with prior history of malignancy who have been disease
free for more than 3 years are eligible.

5. Serious cardiac illness or medical conditions such as unstable angina, pulmonary
embolism, or uncontrolled hypertension.

6. Anti-folate therapy such as methotrexate for rheumatoid arthritis.

7. Baseline peripheral neuropathy CTCAE ≥ Grade 2.

8. Pregnant or lactating women.

9. Other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational
therapy.

10. Active infections (e.g., hepatitis or HIV carriers)

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression free survival(PFS)based on investigator assessment using RECIST v1.1

Outcome Description:

Disease assessment will be conducted via CT/ MRI every 6 weeks while on study. Participants who come off study due to any other reason except progression of disease or death will be followed via CT/ MRI every 6 weeks until disease progression or until start of new therapy.

Outcome Time Frame:

From date of baseline disease assessment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 26 months

Safety Issue:

No

Principal Investigator

Binh Nguyen, MD, PhD

Investigator Role:

Study Director

Investigator Affiliation:

Endocyte

Authority:

United States: Food and Drug Administration

Study ID:

EC-FV-07

NCT ID:

NCT01577654

Start Date:

March 2011

Completion Date:

June 2014

Related Keywords:

  • Non Small Cell Lung Cancer
  • adenocarcinoma
  • squamous
  • adenosquamous
  • adenocarcinoma with other NSCLC variants
  • EC145
  • EC20
  • Vintafolide
  • Etarfolatide
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Roswell Park Cancer InstituteBuffalo, New York  14263
University of Colorado Cancer CenterDenver, Colorado  80262
Washington University School of MedicineSaint Louis, Missouri  63110
Ingalls Memorial HospitalHarvey, Illinois  60426
University of Chicago Medical CenterChicago, Illinois  60637
Gabrail Cancer CenterCanton, Ohio  44718
Oregon Health and Science UniversityPortland, Oregon  97201
Providence Cancer CenterSouthfield, Michigan  48075
Providence Saint Joseph Medical CenterBurbank, California  91505-4866
Ut Southwestern Medical CenterDallas, Texas  75390
Carle Foundation dba Carle Cancer CenterUrbana, Illinois  61801
Ventura County Hematology Oncology SpecialistsOxnard, California  93030
Cancer Care Specialists of Central IllinoisDecatur, Illinois  62256
Horizon Oncology CenterLafayette, Indiana  47905
Willamette Valley Cancer Institute and Research CenterSpringfield, Oregon  97477
Texas Oncology - TylerTyler, Texas  75702
Columbia Basin Hematology and OncologyKennewick, Washington  99336
Penn State Hershey Cancer InstituteHershey, Pennsylvania  17033
Illinois CancerCare, P.C.Bloomington, Illinois  61701
Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer CenterBeaumont, Texas  77702
Texas Oncology - Plano EastPlano, Texas  75075-7787
Texas Oncology-Arlington SouthArlington, Texas  76014
Indiana University - Simon Cancer CenterIndianapolis, Indiana  46202
Texas Oncology-BedfordBedford, Texas  76022
The University of Arizona Cancer Center at UMC-NorthTucson, Arizona  85719
PMK Medical Group, Inc. DBA Ventura County Hematology Oncology SpecialistsOxnard, California  93030
Rush University Mecial CenterChicago, Illinois  60612
Kellogg Cancer CenterEvanston, Illinois  
Carle Cancer Center, Mills Breast Cancer InstituteUrbana, Illinois  
University of Maryland-Marlene and Stewart Greenebaum Cancer CenterBaltimore, Maryland  21201
Barbara Ann Karmanos Cancer InsituteDetroit, Michigan  
Texas Oncology-South AustinAustin, Texas  78731